Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5–8 cm  by Dai, Wing Chiu et al.
ORIGINAL ARTICLE
Radiofrequency ablation versus transarterial chemoembolization for
unresectable solitary hepatocellular carcinomas sized 5–8 cm
Wing Chiu Dai, Tan To Cheung, Kenneth S. H. Chok, Albert C. Y. Chan, William W. Sharr, Simon H. Y. Tsang,
Wai Key Yuen, See Ching Chan, Sheung Tat Fan, Chung Mau Lo & Ronnie T. P. Poon
Department of Surgery, Queen Mary Hospital, University of Hong Kong, Hong Kong, China
Abstract
Objectives: This retrospective review was conducted to compare the efficacy of radiofrequency ablation
(RFA) with that of transarterial chemoembolization (TACE) in treating large (5–8 cm) unresectable solitary
hepatocellular carcinomas (HCCs).
Methods: Patients with large unresectable solitary HCCs primarily treated by RFA or TACE were
reviewed. The primary endpoint was overall survival. Secondary endpoints were tumour response, time
to disease progression, and treatment-related morbidity and mortality.
Results: There were 15 patients in the RFA group. Of these, 12 achieved complete ablation, one had
ablation site recurrence, and five developed complications. Median disease-free survival in this group was
13.0 months (range: 2.8–38.0 months). The TACE group included 26 patients, of whom four obtained a
partial response, none achieved a complete response, and five developed complications. The median
time to disease progression in this group was 8.0 months (range: 1.0–68.0 months). There were no
hospital deaths in this series. Median survival was 39.8 months in the RFA group and 19.8 months in the
TACE group (P = 0.257). Rates of 1-, 2- and 5-year survival were 93.3%, 86.2% and 20.9%, respectively,
in the RFA group and 73.1%, 40.6% and 18.3%, respectively, in the TACE group.
Conclusions: Both RFA and TACE are feasible treatments for large unresectable solitary HCCs. Both
modes show comparable rates of complications and longterm survival, but RFA achieves better initial
tumour control and results in better short-term survival.
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Introduction
Rates of resectability in hepatocellular carcinoma (HCC) patients
referred to surgical units are limited to only 20–37% because of
various factors, such as multifocal or bilobar disease and poor
liver reserve resulting from underlying cirrhosis.1,2 Percutaneous
radiofrequency ablation (RFA) is an effective curative treatment
for solitary HCCs of ≤5 cm in diameter. In a randomized con-
trolled trial (RCT), this treatment modality achieved overall and
disease-free survival rates similar to those obtained by hepatic
resection.3 In other studies, it achieved complete necrosis in
76–100% of treated small HCCs.4–6
However, the management of unresectable solitary HCCs of
>5 cm in size remains controversial.Although liver transplantation
offers cure for such tumours,7,8 the majority of patients cannot
benefit from it because of the shortage of liver grafts, and thus
transarterial chemoembolization (TACE) remains their mainstay
of treatment. The role of RFA in treating HCCs of >5 cm is more
controversial. Complete ablation rates of <50%, which are far from
satisfactory, have been reported.9,10 The present group has previ-
ously reported a complete ablation rate of 83% using a technique
that allows for multiple overlapping ablations to be made from
different angles under intraoperative ultrasound guidance.11
This study was conducted to compare the outcomes of treat-
ment by RFA and TACE, respectively, of unresectable solitary
HCCs measuring 5–8 cm because no such comparison could be
found in the literature published to date.
This study was presented at the 11th World Congress of the IHPBA, 22–27
March 2014, Seoul.
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Materials and methods
The Institutional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West Cluster permits retrospective
studies using data prospectively collected in databases.
Patients
From 2003 to 2010, 2750 patients presented to the Queen Mary
Hospital with HCC. Clinical data for all patients were collected
prospectively. A retrospective study that included all patients
with unresectable solitary HCCs sized 5–8 cm treated by RFA
(the RFA group) or TACE (the TACE group) as primary treat-
ment was performed. In these patients, HCCs were defined as
unresectable as a result of contraindications including significant
comorbidities, the close proximity of the tumour to major
vasculatures, poor liver reserve as indicated by an indocyanine
green clearance test, and Child–Pugh status that precluded major
resection.9,10,12 Radiofrequency ablation was offered if the tumour
location was considered accessible by interventional radiologists
and surgeons.
Assessment of therapeutic efficacy
The primary endpoint was overall survival. Secondary endpoints
were tumour response, time to disease progression, disease-free
survival, and treatment-related morbidity and mortality. Time to
disease progression was calculated from the date of the first treat-
ment to the date of disease progression. Disease-free survival was
calculated as the time from the first treatment to tumour recur-
rence, and was censored at the time of last follow-up or death if at
that time there was no evidence of tumour recurrence. Clinical
data and treatment outcomes were compared between the RFA
and TACE groups.
Response to RFA was assessed by contrast helical computed
tomography (CT) at 1 month after treatment. Complete ablation
was defined as the absence of any enhancement in the arterial
phase at the ablation site. Response to TACE was assessed by CT or
magnetic resonance imaging according to the Response Evalu-
ation Criteria in Solid Tumors (Version 1.1) at 1 month after the
procedure.
A complication was defined as any adverse event after treat-
ment, excluding pain or a transient febrile response. Treatment
mortality was defined as death occurring within 30 days of treat-
ment. All patients with complete ablation after RFA were moni-
tored for intrahepatic recurrence or distant metastasis according
to serum alpha-fetoprotein level, chest radiography and CT every
3 months. Ablation site recurrence was defined as the growth of a
contrast-enhancing lesion within or directly adjacent to the abla-
tion zone if the largest diameter of the lesion was in direct contact
with the ablation zone.13 Distant intrahepatic recurrence was
defined as the occurrence of a new tumour in the liver in an area
distinct from the ablated area. Extrahepatic metastasis referred to
any recurrence outside the liver. Intrahepatic recurrences were
treated with RFA or TACE as deemed appropriate according to
tumour size, number and position, as well as liver function at the
time of recurrence. Patients with extrahepatic metastasis were
treated with systemic therapies (chemotherapy or sorafenib) or
supportive care, depending on their performance status and liver
function.
Ablation procedure
The Cool-tip Radiofrequency System (Covidien, Inc., Mansfield,
MA, USA) was used for RFA. Cluster electrodes consisting of three
parallel electrodes were used for tumours of >5 cm. Ablation was
performed using an impedance control mode in which current
output was automatically adjusted according to the impedance at
the needle tip. Temperature at the needle tip was monitored. The
needle tip was continuously infused with cold saline through a
channel inside the needle during the procedure in order to keep
the temperature of the device at <20 °C and thus to prevent char-
ring around the needle tip. The RFA procedure consisted of
several 12-min cycles. The duration of cycle was shorter for addi-
tional margin ablation. For tumours located close to major portal
pedicles, intraoperative cooling of the bile duct by cold saline
irrigation via a cystic duct cannula was performed to reduce the
risk for bile duct thermal injury.14 Ablations were performed using
a percutaneous, open or laparoscopic approach and with the
intention of achieving a 1.0-cm margin of non-tumorous liver
parenchyma. The percutaneous approach was adopted for
tumours at locations in which this approach could be applied. An
open approach was used when: (i) the tumour was so large that
multiple ablations were required even with the use of cluster elec-
trodes; (ii) the tumour was near the liver dome and thus a percu-
taneous approach might cause pneumothorax or damage to the
diaphragm, and (iii) the tumour was near a visceral organ, such as
the gallbladder, colon or stomach. In selected patients, a
laparoscopic approach was used if the tumour site was accessible.
An i.v. infusion of mannitol was routinely administered before
and during the procedure to reduce the risk for renal impairment
caused by haemoglobinuria.15 Urine colour was monitored and
dipstick tests were performed throughout and after the operation
to monitor for haemoglobinuria.
Transarterial chemoembolization
The technique of TACE has been described previously.16,17
Superselective cannulation of the artery supplying the tumour
was performed whenever possible. An emulsion of cisplatin
(1 mg/ml) and lipiodol (Lipiodol Ultrafluide; Laboratoire
Guerbet, Aulnay-sous-Bois, France) at a volume ratio of 1:1 was
injected up to a maximum of 60 ml, depending on the tumour
size. Embolization was performed with 1.0-mm3 particles of
gelatin sponge (Spongostan; Johnson & Johnson Medical Ltd,
Skipton, UK) mixed with 40 mg of gentamicin sulphate. Follow-
ing the procedure, oral amoxicillin-clavulanic acid (375 mg, thrice
daily) and an H2-blocker were administered for 5 days. Patients, if
clinically fit, were discharged the day after the procedure. The
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TACE procedure was repeated every 8–12 weeks and stopped if
significant disease progression or extrahepatic metastasis was seen
on imaging.
Statistical analysis
Pearson’s chi-squared test or Fisher’s exact test were used to
compare discrete variables. The Mann–Whitney U-test was used
to compare continuous variables. Cumulative survival and
disease-free survival were estimated using the Kaplan–Meier sur-
vival method. Statistical comparisons of survival distribution data
were analysed using the log-rank test. A P-value of <0.05 signified
statistical significance. Statistical analyses were performed using
pasw Statistics for Windows Version 18.0 (SPSS, Inc., Chicago, IL,
USA).
Results
Among the 2750 patients, 645 (23.5%) received resection, 600
(21.8%) received TACE, and 274 (10.0%) received RFA. Of the
1347 (49.0%) patients who presented with solitary HCCs, 150
(11.1%) had tumours measuring 5–8 cm. Of these 150 patients,
99 (66.0%) submitted to tumour resection and 10 (6.7%) under-
went liver transplantation. The remaining 41 (27.3%) patients
underwent either TACE (n = 26; the TACE group) or RFA
(n = 15; the RFA group) as primary treatment. In the latter group,
10 patients underwent open RFA, one underwent laparoscopic
RFA, and four underwent percutaneous RFA (two of them in two
sessions). Demographic data for the two groups are summarized
in Table 1. At the time of writing, median follow-up in the RFA
and TACE groups was 39.5 months (range: 6.1–81.8 months) and
16.5 months (range: 0.7–94.4 months), respectively (P = 0.044).
The rate of treatment-related morbidity was higher in the RFA
group (33.0% versus 19.2%), but the difference was not significant
(P = 0.525) (Table 2). No treatment-associated mortality
occurred. The median total hospital stay for the treatment of the
primary tumour was 8.0 days (range: 1–41 days) in the RFA group
and 8.5 days (range: 1–44 days) in the TACE group (P = 0.616).
The median number of treatment sessions for the primary
tumour was one and varied between one and two in the RFA
group, and 3.5 (range: one to 25) in the TACE group (P < 0.001).
Short- and longterm outcomes
The RFA group
In the RFA group, the median ablation time was 60 min (range:
12–102 min). Complete ablation was achieved in 12 patients. In
one patient submitted to percutaneous RFA, the procedure was
performed in two separate sessions. Three patients (with HCCs
Table 1 Comparison of characteristics of the two groups of patients
RFA group (n = 15) TACE (n = 26) P-value
Age, years, median (range) 63 (32–82) 64.5 (50–84) 0.718
Male : female ratio 13:2 21:5 0.958
Aetiology: alcohol, n 0.241
No 7 17
Yes 8 9
Hepatitis B virus carrier, n 10 18 1
Hepatitis C virus carrier, n 2 5 0.472
Child–Pugh class, n 0.410
A 12 22
B 2 4
C 1 0
Tumour size, cm, median (range) 6.0 (5.2–8.0) 6.7 (5.1–8.0) 0.242
Tumour staginga, n 1
Stage I 13 23
Stage IIIb 2 3
Total bilirubin, μmol/l, median (range) 14 (5–33) 12 (4–38) 0.904
Albumin, g/l, median (range) 39.0 (31–43) 36.5 (27–45) 0.091
INR, median (range) 1.1 (0.9–1.2) 1.1 (0.9–2.0) 0.820
Platelet count, ×109/l, median (range) 124.0 (62–248) 134.5 (28–378) 0.529
Creatinine, μmol/l, median (range) 86.0 (59–654) 93.5 (55–533) 0.779
Alpha-fetoprotein, ng/ml, median (range) 10.0 (2–97 200) 109.5 (2–237 900) 0.369
aAmerican Joint Committee on Cancer 2002, 6th edition.
INR, international normalized ratio.
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sized 6 cm, 6.5 cm and 8 cm, respectively) had residual disease;
one of these patients underwent a second RFA procedure. Abla-
tion site recurrence occurred in one patient at 4.0 months after the
initial percutaneous RFA. Nine patients developed intrahepatic
recurrence, two patients developed extrahepatic metastasis, and
another two patients developed both. Six patients received TACE
and five patients received further RFA for intrahepatic recurrence.
The median disease-free survival was 13.0 months (range: 2.8–
38.0 months). Rates of disease-free survival at 1, 3 and 5 years were
56.3%, 10.0% and 0%, respectively. Median overall survival was
39.8 months (range: 6.1–81.8 months). Rates of overall survival at
1, 3 and 5 years were 93.3%, 70.5% and 20.9%, respectively
(Fig. 1).
The TACE group
Twenty-six patients received TACE as primary treatment of HCC.
The median number of cycles of TACE was three (range: one to
25). No patient achieved a complete response, but four patients
obtained a partial response. The median time to disease progres-
sion was 8.0 months (range: 1.0–68.0 months). Six patients devel-
oped extrahepatic metastasis. Median overall survival was 19.8
months (range: 0.7–94.4 months). Rates of 1-year, 3-year and
5-year overall survival were 73.1%, 30.4% and 18.3%, respectively.
The two groups did not differ significantly in terms of overall
survival (P = 0.257), although the median duration of overall
survival was shorter in the TACE group (19.8 months versus
39.8 months) (Fig. 1).
Discussion
Radiofrequency ablation is considered by some to be as effective as
resection for small HCCs. For larger HCCs, however, it is less
effective. Reported percentages of patients in whom complete
necrosis in larger HCCs was achieved by RFA vary between 29%
and 83%.9–11,18 These suboptimal results reflect the fact that
coagulative necrosis induced by RFA alone can be limited.
However, it has been reported that the multipolar RFA technique
can achieve the complete ablation of liver tumours of up to 7.4 cm
in size.19–22 Bowles et al.23 also demonstrated RFA to be safe even in
large tumours in a series in which tumours of up to 18 cm were
ablated and morbidity and recurrence rates were 7% and 9%,
respectively. Yin et al.24 reported their experience of treating 109
patients with HCCs sized 3–7 cm by percutaneous thermal abla-
tion using RFA or microwave ablation. The complete ablation rate
was 92.6%, local recurrence occurred in 22.0% of patients and the
median time to local recurrence was 4.6 months. Yin et al.24 found
that patients with tumours measuring 5–7 cm achieved 1-, 2-, 3-
and 5-year post-ablation survival rates similar to those of patients
with tumours measuring 3–5 cm (P = 0.84).
In the present study, a complete ablation rate of 80.0% was
achieved in patients who received RFA as the definitive treatment,
and the local recurrence rate was 6.7%. These results are remark-
able in comparison with those reported in the literature and can
be attributed to the fact that most patients underwent open rather
than percutaneous RFA. In a meta-analysis of outcomes in 5224
liver tumours treated by RFA, treatment approach was found to be
a significant independent factor associated with local recurrence.25
Transarterial chemoembolization takes advantage of the rela-
tively selective arterial vascularization of liver tumours and is
intended to achieve tumour ischaemia. In the treatment, the deliv-
ery of chemotherapeutic agents and the embolization of
blood vessels are performed simultaneously to increase local
Table 2 Comparison of treatment-related morbidity and mortality in
the two groups
RFA
group
(n = 15)
TACE
group
(n = 26)
P-value
Hospital deaths, n 0 0
Patients with complication, n 5 5 0.525
Liver abscess 1
Bleeding oesophageal varices 2
Liver function derangement 2
Chest infection 1
Pleural effusion 2
Haemobilia 1
Haemoglobinuria 1
Figure 1 Comparison of overall survival of the two groups of patients
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chemotherapeutic dwell time. Two randomized trials have shown
TACE to improve the survival of patients with unresectable
HCCs.16,26 A recent meta-analysis comparing TACE and conserva-
tive treatment reported the former to offer a significant survival
benefit over the latter.27
A recent study reported that patients who underwent hepatec-
tomy or living-donor liver transplantation as a primary treatment
for solitary HCC sized 5–8 cm achieved 5-year overall survival
rates of 68.9% and 87.5%, respectively.28 A comparison of the
relative efficacy of TACE and RFA in treating patients with
unresectable HCCs of ≥5 cm is lacking in the literature. Given the
controversy over the management of this group of patients, the
findings of the present study are significant. In the present study,
RFA was found to surpass TACE in immediate tumour control,
which reflects the results of a previous study by this group in
patients with multiple and unresectable HCCs of <5 cm.29 In the
present study, the median time to disease progression was 8.0
months (range: 1.0–68.0 months) in patients treated with TACE
and median disease-free survival was 13.0 months (range: 3.0–
38.0 months) in patients treated with RFA. A complete ablation,
which reduces the patient’s tumour load, may benefit the patient
in the short term. Median survival was 39.8 months in the RFA
group and 19.8 months in the TACE group and thus did not differ
significantly (P = 0.257). This might be explained by the small
number of patients in the study. The RFA group achieved a much
higher 2-year survival rate than the TACE group (86.2% versus
40.6%), although the two groups had similar rates of 5-year sur-
vival (20.9% and 18.3%, respectively). The similarity in 5-year
survival reflects the fact that the natural history and biology of
HCC cannot be altered by local ablative therapies. No in-hospital
mortality occurred in this series, and the two treatment modalities
were both well tolerated. The complication rate was insignificantly
higher in the RFA group (33.3% versus 19.2%; P = 0.525), and
higher than that reported by Mulier et al.,30 probably because
more of the procedures (10 of 15) were performed in open
surgery.
The present study was not a randomized trial and is inevitably
subject to weaknesses such as bias. Nonetheless, it is the first study
to demonstrate a probable short- to mid-term advantage of RFA
over TACE for solitary unresectable HCCs of 5–8 cm in size,
although no significant difference in longterm survival was found.
In the present study, conventional cisplatin-based TACE was
used. Whether the use of drug-eluting beads in TACE would
produce a different outcome is unknown.31 A recent RCT showed
that RFA combined with TACE is more effective than RFA alone in
extending the ablated area and decreasing the local tumour pro-
gression rate in patients with medium-sized HCCs.32 Some
authors believe that TACE can work in synergism with RFA
because the heat-sink effect is reduced after embolization and
tumour cells are more sensitive to hyperthermia after TACE.33
Whether the combination of these two treatment modalities has a
synergistic effect in patients with unresectable large HCCs needs
to be investigated further.
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